Vincristine

SKU: orb1303432

Description

Vincristine is a microtubule-destabilizing alkaloid that inhibits mitosis by binding tubulin, making it a key research tool for studying hematologic cancers and pediatric sarcomas in both in vitro and in vivo models.

Research Area

Infectious Disease & Virology, Pharmacology & Drug Discovery, Signal Transduction

Key Properties

• CAS Number: 57-22-7
• MW: 824.96
• Purity: 98.46% (May vary between batches)
• Formula: C₄₆H₅₆N₄O₁₀
• SMILES: CC[C@]1(O)C[C@@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC
• Target: JNK,Akt,Microtubule Associated,Antibiotic,mTOR,ERK,p38 MAPK,NF-κB
• Solubility: DMSO:12 mg/mL (14.55 mM);10% DMSO+40% PEG300+5% Tween-80+45% Saline:1 mg/mL (1.21 mM)

Bioactivity

• In Vivo:
  METHODS: To assay antitumor activity in vivo, Vincristine (0.025 mg/kg, intravenously, once weekly) and SAHA (200 mg/kg, orally, once daily) were administered to SCID mice bearing MOLT-4 xenografts for 24 days. RESULTS: TGD did not improve in mice treated with Vincristine or SAHA alone. However, log-rank analysis showed that co-treatment exhibited significant anti-tumor activity in the MOLT-4 xenograft model.
• In Vitro:
  METHODS: Neuroblastoma cells SH-SY5Y were treated with Vincristine (0.001-10 µM) for 24-72 h. Cell viability was measured by MTT assay. RESULTS: Vincristine inhibited the proliferation of SH-SY5Y cells in a dose- and time-dependent manner, with IC50s of 0.113 µM, 0.078 µM, and 0.051 µM at 24, 48, and 72 h, respectively. METHODS: Human leukemia cells MOLT-4 were treated with Vincristine (0.3-3 µM) and SAHA (500 nM) for 24-48 h. Cell cycle was detected using Flow cytometry. RESULTS: Vincristine treatment induced an increase in the G2/M phase of the cell cycle compared to SAHA. the combination of Vincristine plus SAHA resulted in almost complete cell arrest in the G2/M phase after short-term treatment (24 h), followed by induction of the cells into the sub-G1 phase after long-term treatment (48 h). the combination of Vincristine and SAHA resulted in an increase in the G2/M phase of the cell cycle compared to SAHA.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

inhibit, JNK, mTOR, NSC67574, NSC-67574, NF-κB, NFκB, NF-kB, NFkB, NSC 67574, Microtubule/Tubulin, ERK, Inhibitor, Leurocristine, Antibiotic, 22-Oxovincaleukoblastine, Akt, p38MAPK, p38 MAPK, Vincristine

Compound Identifiers

PubChem CID

5388993